DK1289534T3 - Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser - Google Patents

Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser

Info

Publication number
DK1289534T3
DK1289534T3 DK01935896T DK01935896T DK1289534T3 DK 1289534 T3 DK1289534 T3 DK 1289534T3 DK 01935896 T DK01935896 T DK 01935896T DK 01935896 T DK01935896 T DK 01935896T DK 1289534 T3 DK1289534 T3 DK 1289534T3
Authority
DK
Denmark
Prior art keywords
apoptotic
treatment
inflammatory disorders
devices
cell mediated
Prior art date
Application number
DK01935896T
Other languages
Danish (da)
English (en)
Inventor
Anthony E Bolton
Daniel Sauder
Arkady Mandel
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of DK1289534T3 publication Critical patent/DK1289534T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
DK01935896T 2000-05-25 2001-05-25 Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser DK1289534T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2309518 CA2309518A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Publications (1)

Publication Number Publication Date
DK1289534T3 true DK1289534T3 (da) 2006-03-20

Family

ID=4166254

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01935896T DK1289534T3 (da) 2000-05-25 2001-05-25 Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser

Country Status (11)

Country Link
US (1) US20020051771A1 (enExample)
EP (2) EP1289534B1 (enExample)
JP (1) JP2003534281A (enExample)
AT (1) ATE311191T1 (enExample)
AU (1) AU2001261986A1 (enExample)
CA (1) CA2309518A1 (enExample)
DE (1) DE60115432T2 (enExample)
DK (1) DK1289534T3 (enExample)
ES (1) ES2254424T3 (enExample)
TW (1) TWI249404B (enExample)
WO (1) WO2001089536A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
CA2457015C (en) * 2001-08-13 2012-03-13 Richard L. Edelson Method for inducing selectively suppressed immune response
US7727523B2 (en) * 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CA2893962C (en) * 2012-12-06 2021-04-06 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11512289B2 (en) * 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
JP6884155B2 (ja) * 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
WO2023209709A1 (en) * 2022-04-27 2023-11-02 Enlivex Therapeutics Rdo Ltd Apoptotic cell - chemotherapy combination therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法

Also Published As

Publication number Publication date
US20020051771A1 (en) 2002-05-02
WO2001089536A2 (en) 2001-11-29
EP1289534A2 (en) 2003-03-12
AU2001261986A1 (en) 2001-12-03
ES2254424T3 (es) 2006-06-16
ATE311191T1 (de) 2005-12-15
JP2003534281A (ja) 2003-11-18
WO2001089536A3 (en) 2002-08-01
DE60115432T2 (de) 2006-08-24
EP1289534B1 (en) 2005-11-30
HK1055079A1 (en) 2003-12-24
CA2309518A1 (en) 2001-11-25
EP1669081A1 (en) 2006-06-14
TWI249404B (en) 2006-02-21
DE60115432D1 (de) 2006-01-05

Similar Documents

Publication Publication Date Title
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
GEP20063799B (en) Tropane derivatives useful in therapy
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
DK1071439T3 (da) Hybenformuleringer som antiinflammatorisk naturmedicin til lindring/reduktion af symptomer associeret med inflammation og artritis
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
DK0607128T3 (da) Lægemiddel samt fremstilling deraf og anvendelse deraf ved bekæmpelsen af smerter og/eller betændelser hos dyr og mennesker
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
NO20060424L (no) 5-heteroringbaserte P38 kinaseinhibitorer
BR0014912A (pt) Tratamento de distúrbios do sono usando desloratadina
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
ATE232396T1 (de) Oxydiertes thymosin beta 4
NO20013004D0 (no) Anvendelse av biokjemiske substanser i en sammensetning for forhindringen og behandlingen av helsetilstander forårsaket avkonstriksjon av glattmuskelceller i organer i det menneskeligelegemet
DK1289535T3 (da) Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme
AR037524A1 (es) Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
IT1318667B1 (it) Medicamento antinfiammatorio.
SE0004101D0 (sv) New use
WO2001089538A3 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
ATE417620T1 (de) Antipyretikum und herstellungsverfahren dafür
NZ515173A (en) Treatment of hypersensitivity reaction disorders
ATE285243T1 (de) Medizinische salbe sowie deren herstellungsverfahren